Elidel is a prescription-only topical medication that contains pimecrolimus as its active ingredient. It is supplied in a tube formulation with two strengths-10 g and 30 g-each delivering a 0.1 % (w/w) concentration of the drug. Elidel belongs to the skin-care therapeutic category and is classified as a topical calcineurin inhibitor. In Hong Kong, the product is regulated by the Department of Health’s Pharmacy and Poisons Board and is available only with a medical prescription.
Pimecrolimus belongs to a class of medicines called calcineurin inhibitors. In the skin, it penetrates the epidermis and binds to a protein called FKBP-12. This complex then blocks the activity of the enzyme calcineurin, which is essential for activating T-cells-a type of white blood cell involved in inflammatory responses. By inhibiting calcineurin, pimecrolimus reduces the release of inflammatory cytokines (such as interleukin-2 and interferon-γ) that drive the redness, itching, and swelling characteristic of atopic dermatitis and other inflammatory skin conditions.
Because the drug works locally on the skin and is minimally absorbed into the bloodstream, its systemic effects are limited, making it a useful alternative to topical corticosteroids for long-term management of chronic skin inflammation.
Elidel is FDA-approved and HK-licensed for the short-term and intermittent chronic treatment of mild to moderate atopic dermatitis (eczema) in patients aged 2 years and older. The medication is intended for areas where the skin is inflamed but not infected, such as the elbows, knees, hands, and the trunk.
While the label does not include other skin disorders, clinicians sometimes prescribe pimecrolimus off-label for conditions such as contact dermatitis, seborrheic dermatitis, and lichen planus, provided that the benefits outweigh the risks and the patient is closely monitored.
These reactions usually diminish after several days of continued use. If they persist or worsen, discontinue and seek medical advice.
Systemic absorption of pimecrolimus is minimal; therefore, clinically significant drug-drug interactions are uncommon. However:
Patients should inform their healthcare provider of all prescription medicines, over-the-counter drugs, supplements, and herbal products before starting Elidel.
This article provides educational information about Elidel and is not a substitute for professional medical advice. Treatment decisions, including the use of any medication for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Elidel may be applied to facial skin in patients aged 2 years and older, but care should be taken to avoid the eye area and to monitor for local irritation. If persistent burning occurs, discontinue use and seek medical advice.
The duration depends on the size and number of lesions treated. For a typical mild-to-moderate atopic dermatitis flare affecting a few areas, a 10 g tube can last 2-4 weeks when applied twice daily.
Limited data exist on pimecrolimus transfer into breast milk. Because systemic absorption is low, many clinicians consider it relatively safe, but it should only be used if the expected benefit outweighs potential risks and after discussion with a healthcare provider.
Yes. Elidel is a prescription-only medication regulated by the Hong Kong Department of Health’s Pharmacy and Poisons Board. It cannot be purchased over the counter.
Applying a gentle, fragrance-free moisturizer after the medication has been absorbed (typically 5-10 minutes) can help alleviate dryness and improve skin barrier function.
Stop using Elidel immediately and contact a healthcare professional. The infection may require topical or oral antimicrobial therapy before resuming any anti-inflammatory treatment.
Current evidence does not confirm a causal link between topical pimecrolimus and skin cancer. Nevertheless, regular skin examinations are advisable for patients on prolonged therapy, especially those with a history of skin malignancies.
No. Elidel should not be applied to open wounds, ulcerated skin, or areas with active infection, as absorption may increase and irritation risk rises.
Pimecrolimus does not increase photosensitivity, but patients with eczema often have compromised skin barriers. Using a broad-spectrum sunscreen on unaffected areas is recommended for overall skin health.
Both reduce inflammation, but Elidel does not cause steroid-related side effects such as skin thinning, striae, or telangiectasia. It is especially useful for long-term management when steroid fatigue or side effects are a concern. However, steroids may provide faster relief for severe flares.
